Adstiladrin received FDA approval on December 16, 2022. It represents a significant advancement in cancer therapy, particularly for patients who have not responded to standard treatments.

Adagrasib, marketed under the brand name Krazati, is an oral medication used to treat adults with non-small cell lung cancer (NSCLC).

Olutasidenib received FDA approval on December 1, 2022. This drug belongs to the class of miscellaneous antineoplastics.

Rebyota, a fecal microbiota product, is used to prevent the recurrence of Clostridioides difficile infection (CDI).

Etranacogene dezaparvovec, marketed under the brand name Hemgenix, is a gene therapy used to treat adults with Hemophilia B.

Teplizumab, marketed under the brand name Tzield, was approved by the FDA on November 17, 2022.

Mirvetuximab soravtansine, marketed under the brand name Elahere, is approved by the FDA for the treatment of adults with ovarian cancer.

Tremelimumab (brand name: Imjudo) is indeed FDA-approved. It is a monoclonal antibody that belongs to the class of drugs known as anti-CTLA-4 monoclonal antibodies.

Futibatinib (brand name: Lytgobi) is an FDA-approved medication used to treat certain types of bile duct cancer (cholangiocarcinoma).

Gadopiclenol, known by its brand names Elucirem, Vueway, and Elucirem Prefilled Syringe, was approved by the FDA on September 21, 2022.

Terlipressin, marketed under the brand name Terlivaz, was approved by the FDA on September 14, 2022.

Deucravacitinib, marketed under the brand name Sotyktu, was approved by the FDA on September 9, 2022.